Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade

BACKGROUND: Immune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between African American (AA) and Caucasian mRCC patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, T. Anders, Martini, Dylan J., Goyal, Subir, Liu, Yuan, Evans, Sean T., Magod, Benjamin, Brown, Jacqueline T., Yantorni, Lauren, Russler, Greta Anne, Caulfield, Sarah, Goldman, Jamie M., Harris, Wayne B., Kucuk, Omer, Carthon, Bradley C., Master, Viraj A., Nazha, Bassel, Bilen, Mehmet Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242950/
https://www.ncbi.nlm.nih.gov/pubmed/34222024
http://dx.doi.org/10.3389/fonc.2021.701345

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242950/
https://www.ncbi.nlm.nih.gov/pubmed/34222024
http://dx.doi.org/10.3389/fonc.2021.701345

Ejemplares similares